The kidney research community needs to change. We're all passionate experts. We care deeply. But we're not seeing the progress that kidney patients need. To be blunt, we need to do more, and faster....

The author describes the scientific basis for a trial of an MC4R agonist in persons with acquired hypothalamic obesity. Those who received the drug had reductions in body-mass index and hunger.

A phase 2 trial of setmelanotide, a melanocortin-4 receptor agonist, showed substantial weight loss in patients with acquired hypothalamic obesity, but additional data are needed. We conducted a ph...

Hormones act across tissues and organs to coordinate physiological functions. Drawing inspiration from the Human Cell Atlas, we analyzed expression of 379 hormone and receptor genes in a transcriptomi...

Analyzing data from the SURMOUNT-1 trial, the authors show that the weight loss effects of tirzepatide treatment are similar in carriers and noncarriers of MC4R pathogenic mutations.

The authors explore the impact of MC4R deficiency on lipid metabolism in humans, based on two large cohorts. Findings indicate that individuals with obesity due to MC4R deficiency have lower cholester...

Professor Farooqi has been awarded the esteemed Gerald D. Aurbach Award for Outstanding Translational Research. This is the second year running that a Cambridge BRC researcher in the field of metaboli...